USP10 (Ubiquitin Specific Peptidase 10)
A deubiquitinating enzyme involved in p53 stability, stress granule dynamics, and antiviral signaling.
Gene Information Card
| Symbol | USP10 |
|---|---|
| Full Name | Ubiquitin Specific Peptidase 10 |
| Gene Type | Protein coding |
| Chromosomal Location | 16q24.1 |
| NCBI Gene ID | 9100 ncbi.nlm.nih.gov/gene/9100 |
| Ensembl ID | ENSG00000103197 |
| UniProt ID | Q14694 |
| OMIM ID | 609818 |
| HGNC ID | 12616 |
| Aliases | UBP10, KIAA0190, FLJ12572 |
Description
USP10 (Ubiquitin Specific Peptidase 10) encodes a deubiquitinating enzyme that removes ubiquitin from specific substrates, thereby regulating protein stability, localization, and function. It is best known for deubiquitinating and stabilizing p53 (TP53) in response to DNA damage, and for modulating stress granule assembly and antiviral innate immunity. USP10 also interacts with the androgen receptor and is implicated in cancer, neurodegenerative disorders, and viral infections.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | USP10 overexpression stabilizes p53, but in some contexts promotes tumor growth via AR signaling; altered expression correlates with poor prognosis. | PubMed (PMID: 20850012, 27307490) |
| Prostate cancer | USP10 deubiquitinates androgen receptor, enhancing its transcriptional activity and promoting castration-resistant growth. | PubMed (PMID: 27307490) |
| Hepatocellular carcinoma | USP10 loss or downregulation reduces p53 stability, contributing to tumor progression. | PubMed (PMID: 25944712) |
| Neurodegenerative diseases (e.g., ALS, FTD) | USP10 localizes to stress granules; mutations or dysregulation impair stress granule dynamics, linked to TDP-43 pathology. | PubMed (PMID: 25464849) |
| Viral infections (e.g., SARS-CoV-2, influenza) | USP10 restricts viral replication by deubiquitinating antiviral signaling molecules (e.g., MAVS, STING). | PubMed (PMID: 32345962) |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Lung | 8.3 | Low |
| Liver | 15.7 | Medium |
| Kidney | 10.2 | Medium |
| Testis | 20.1 | High |
| Breast | 9.8 | Low |
| Prostate | 11.4 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 18.5 | High expression |
| HeLa | 14.2 | Medium expression |
| MCF7 | 12.8 | Medium expression |
| HepG2 | 16.1 | Medium-high expression |
| A549 | 9.7 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1012C>T (p.Arg338*) | Nonsense | <0.1% | Loss of function; predicted to cause nonsense-mediated decay |
| c.1543G>A (p.Gly515Arg) | Missense | <0.1% | Unknown; located in catalytic domain |
| c.2110A>G (p.Thr704Ala) | Missense | <0.1% | Unknown; may affect substrate binding |
| c.256_258del (p.Lys86del) | In-frame deletion | <0.1% | Unknown; near UBP domain |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations that truncate the protein or disrupt the catalytic domain are predicted to impair deubiquitinase activity, reducing p53 stability and promoting tumorigenesis.
Gain of Function (GOF)
No well-characterized gain-of-function mutations have been reported in USP10.
Dominant Negative (DN)
No dominant-negative mutations have been described for USP10.
View complete mutation data：
Gene Ontology (GO)
| • cysteine-type deubiquitinase activity | • ubiquitin-specific protease activity |
| • protein deubiquitination | • stress granule assembly |
| • regulation of protein stability | • positive regulation of DNA damage response |
| • innate immune response | • viral process |
Pathways
• p53 signaling pathway
• Deubiquitination
• Androgen receptor signaling
• RIG-I/MDA5 mediated induction of IFN-alpha/beta
• Stress granule formation
Protein Summary
USP10 is a 798-amino acid deubiquitinating enzyme containing a conserved ubiquitin-specific protease (USP) domain. It cleaves ubiquitin from target proteins, including p53, the androgen receptor, and components of antiviral signaling (MAVS, STING). USP10 shuttles between the nucleus and cytoplasm, and localizes to stress granules under cellular stress. Its activity is critical for maintaining p53 protein levels, modulating androgen receptor function, and regulating innate immune responses. Dysregulation of USP10 is linked to cancer, neurodegeneration, and viral pathogenesis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| DUSP10 Knockout HEK293 Cell Line | EDJ-KQ640 | Human | 11221 | Details Get a Quote |
| USP10 Knockout HEK293 Cell Line | EDJ-KQ2504 | Human | 9100 | Details Get a Quote |
| DUSP10 Knockout A-549 Cell Line | EDJ-KQ19115 | Human | 11221 | Details Get a Quote |
| DUSP10 Knockout HCT 116 Cell Line | EDJ-KQ19116 | Human | 11221 | Details Get a Quote |
| DUSP10 Knockout HeLa Cell Line | EDJ-KQ19117 | Human | 11221 | Details Get a Quote |
| USP10 Knockout HCT 116 Cell Line | EDJ-KQ23099 | Human | 9100 | Details Get a Quote |
| USP10 Knockout HeLa Cell Line | EDJ-KQ23100 | Human | 9100 | Details Get a Quote |
| USP10 Knockout A-549 Cell Line | EDJ-KQ21736 | Human | 9100 | Details Get a Quote |
| USP10 Knockout HAP1 Cell Line | EDC07999 | Human | 9100 | Details Get a Quote |
Displaying Records 1 To 9 Of 9 Records
